Research ExplorerPublicationsDaratumumab, bortezomib, and dexamethasone in relapsed or re...

Daratumumab, bortezomib, and dexamethasone in relapsed or refractory multiple myeloma: subgroup analysis of CASTOR based on cytogenetic risk

Standard

Daratumumab, bortezomib, and dexamethasone in relapsed or refractory multiple myeloma: subgroup analysis of CASTOR based on cytogenetic risk. / Weisel, Katja; Spencer, Andrew; Lentzsch, Suzanne; Avet-Loiseau, Hervé; Mark, Tomer M; Spicka, Ivan; Masszi, Tamas; Lauri, Birgitta; Levin, Mark-David; Bosi, Alberto; Hungria, Vania; Cavo, Michele; Lee, Je-Jung; Nooka, Ajay; Quach, Hang; Munder, Markus; Lee, Cindy; Barreto, Wolney; Corradini, Paolo; Min, Chang-Ki; Chanan-Khan, Asher A; Horvath, Noemi; Capra, Marcelo; Beksac, Meral; Ovilla, Roberto; Jo, Jae-Cheol; Shin, Ho-Jin; Sonneveld, Pieter; Casneuf, Tineke; DeAngelis, Nikki; Amin, Himal; Ukropec, Jon; Kobos, Rachel; Mateos, Maria-Victoria.

In: J HEMATOL ONCOL, Vol. 13, No. 1, 20.08.2020, p. 115.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Weisel, K, Spencer, A, Lentzsch, S, Avet-Loiseau, H, Mark, TM, Spicka, I, Masszi, T, Lauri, B, Levin, M-D, Bosi, A, Hungria, V, Cavo, M, Lee, J-J, Nooka, A, Quach, H, Munder, M, Lee, C, Barreto, W, Corradini, P, Min, C-K, Chanan-Khan, AA, Horvath, N, Capra, M, Beksac, M, Ovilla, R, Jo, J-C, Shin, H-J, Sonneveld, P, Casneuf, T, DeAngelis, N, Amin, H, Ukropec, J, Kobos, R & Mateos, M-V 2020, 'Daratumumab, bortezomib, and dexamethasone in relapsed or refractory multiple myeloma: subgroup analysis of CASTOR based on cytogenetic risk', J HEMATOL ONCOL, vol. 13, no. 1, pp. 115. https://doi.org/10.1186/s13045-020-00948-5

APA

Weisel, K., Spencer, A., Lentzsch, S., Avet-Loiseau, H., Mark, T. M., Spicka, I., Masszi, T., Lauri, B., Levin, M-D., Bosi, A., Hungria, V., Cavo, M., Lee, J-J., Nooka, A., Quach, H., Munder, M., Lee, C., Barreto, W., Corradini, P., ... Mateos, M-V. (2020). Daratumumab, bortezomib, and dexamethasone in relapsed or refractory multiple myeloma: subgroup analysis of CASTOR based on cytogenetic risk. J HEMATOL ONCOL, 13(1), 115. https://doi.org/10.1186/s13045-020-00948-5

Vancouver

Weisel K, Spencer A, Lentzsch S, Avet-Loiseau H, Mark TM, Spicka I et al. Daratumumab, bortezomib, and dexamethasone in relapsed or refractory multiple myeloma: subgroup analysis of CASTOR based on cytogenetic risk. J HEMATOL ONCOL. 2020 Aug 20;13(1):115. https://doi.org/10.1186/s13045-020-00948-5

Bibtex

@article{7a49493692c742e2abeb0ac1c18365f0,
title = "Daratumumab, bortezomib, and dexamethasone in relapsed or refractory multiple myeloma: subgroup analysis of CASTOR based on cytogenetic risk",
abstract = "BACKGROUND: Multiple myeloma (MM) patients with high cytogenetic risk have poor outcomes. In CASTOR, daratumumab plus bortezomib/dexamethasone (D-Vd) prolonged progression-free survival (PFS) versus bortezomib/dexamethasone (Vd) alone and exhibited tolerability in patients with relapsed or refractory MM (RRMM).METHODS: This subgroup analysis evaluated D-Vd versus Vd in CASTOR based on cytogenetic risk, determined using fluorescence in situ hybridization and/or karyotype testing performed locally. High-risk patients had t(4;14), t(14;16), and/or del17p abnormalities. Minimal residual disease (MRD; 10-5 sensitivity threshold) was assessed via the clonoSEQ{\textregistered} assay V2.0. Of the 498 patients randomized, 40 (16%) in the D-Vd group and 35 (14%) in the Vd group were categorized as high risk.RESULTS: After a median follow-up of 40.0 months, D-Vd prolonged median PFS versus Vd in patients with standard (16.6 vs 6.6 months; HR, 0.26; 95% CI, 0.19-0.37; P < 0.0001) and high (12.6 vs 6.2 months; HR, 0.41; 95% CI, 0.21-0.83; P = 0.0106) cytogenetic risk. D-Vd achieved deep responses, including higher rates of MRD negativity and sustained MRD negativity versus Vd, regardless of cytogenetic risk. The safety profile was consistent with the overall population of CASTOR.CONCLUSION: These updated data reinforce the effectiveness and tolerability of daratumumab-based regimens for RRMM, regardless of cytogenetic risk status.TRIAL REGISTRATION: ClinicalTrials.gov, NCT02136134 . Registered 12 May 2014.",
author = "Katja Weisel and Andrew Spencer and Suzanne Lentzsch and Herv{\'e} Avet-Loiseau and Mark, {Tomer M} and Ivan Spicka and Tamas Masszi and Birgitta Lauri and Mark-David Levin and Alberto Bosi and Vania Hungria and Michele Cavo and Je-Jung Lee and Ajay Nooka and Hang Quach and Markus Munder and Cindy Lee and Wolney Barreto and Paolo Corradini and Chang-Ki Min and Chanan-Khan, {Asher A} and Noemi Horvath and Marcelo Capra and Meral Beksac and Roberto Ovilla and Jae-Cheol Jo and Ho-Jin Shin and Pieter Sonneveld and Tineke Casneuf and Nikki DeAngelis and Himal Amin and Jon Ukropec and Rachel Kobos and Maria-Victoria Mateos",
year = "2020",
month = aug,
day = "20",
doi = "10.1186/s13045-020-00948-5",
language = "English",
volume = "13",
pages = "115",
journal = "J HEMATOL ONCOL",
issn = "1756-8722",
publisher = "BioMed Central Ltd.",
number = "1",

}

RIS

TY - JOUR

T1 - Daratumumab, bortezomib, and dexamethasone in relapsed or refractory multiple myeloma: subgroup analysis of CASTOR based on cytogenetic risk

AU - Weisel, Katja

AU - Spencer, Andrew

AU - Lentzsch, Suzanne

AU - Avet-Loiseau, Hervé

AU - Mark, Tomer M

AU - Spicka, Ivan

AU - Masszi, Tamas

AU - Lauri, Birgitta

AU - Levin, Mark-David

AU - Bosi, Alberto

AU - Hungria, Vania

AU - Cavo, Michele

AU - Lee, Je-Jung

AU - Nooka, Ajay

AU - Quach, Hang

AU - Munder, Markus

AU - Lee, Cindy

AU - Barreto, Wolney

AU - Corradini, Paolo

AU - Min, Chang-Ki

AU - Chanan-Khan, Asher A

AU - Horvath, Noemi

AU - Capra, Marcelo

AU - Beksac, Meral

AU - Ovilla, Roberto

AU - Jo, Jae-Cheol

AU - Shin, Ho-Jin

AU - Sonneveld, Pieter

AU - Casneuf, Tineke

AU - DeAngelis, Nikki

AU - Amin, Himal

AU - Ukropec, Jon

AU - Kobos, Rachel

AU - Mateos, Maria-Victoria

PY - 2020/8/20

Y1 - 2020/8/20

N2 - BACKGROUND: Multiple myeloma (MM) patients with high cytogenetic risk have poor outcomes. In CASTOR, daratumumab plus bortezomib/dexamethasone (D-Vd) prolonged progression-free survival (PFS) versus bortezomib/dexamethasone (Vd) alone and exhibited tolerability in patients with relapsed or refractory MM (RRMM).METHODS: This subgroup analysis evaluated D-Vd versus Vd in CASTOR based on cytogenetic risk, determined using fluorescence in situ hybridization and/or karyotype testing performed locally. High-risk patients had t(4;14), t(14;16), and/or del17p abnormalities. Minimal residual disease (MRD; 10-5 sensitivity threshold) was assessed via the clonoSEQ® assay V2.0. Of the 498 patients randomized, 40 (16%) in the D-Vd group and 35 (14%) in the Vd group were categorized as high risk.RESULTS: After a median follow-up of 40.0 months, D-Vd prolonged median PFS versus Vd in patients with standard (16.6 vs 6.6 months; HR, 0.26; 95% CI, 0.19-0.37; P < 0.0001) and high (12.6 vs 6.2 months; HR, 0.41; 95% CI, 0.21-0.83; P = 0.0106) cytogenetic risk. D-Vd achieved deep responses, including higher rates of MRD negativity and sustained MRD negativity versus Vd, regardless of cytogenetic risk. The safety profile was consistent with the overall population of CASTOR.CONCLUSION: These updated data reinforce the effectiveness and tolerability of daratumumab-based regimens for RRMM, regardless of cytogenetic risk status.TRIAL REGISTRATION: ClinicalTrials.gov, NCT02136134 . Registered 12 May 2014.

AB - BACKGROUND: Multiple myeloma (MM) patients with high cytogenetic risk have poor outcomes. In CASTOR, daratumumab plus bortezomib/dexamethasone (D-Vd) prolonged progression-free survival (PFS) versus bortezomib/dexamethasone (Vd) alone and exhibited tolerability in patients with relapsed or refractory MM (RRMM).METHODS: This subgroup analysis evaluated D-Vd versus Vd in CASTOR based on cytogenetic risk, determined using fluorescence in situ hybridization and/or karyotype testing performed locally. High-risk patients had t(4;14), t(14;16), and/or del17p abnormalities. Minimal residual disease (MRD; 10-5 sensitivity threshold) was assessed via the clonoSEQ® assay V2.0. Of the 498 patients randomized, 40 (16%) in the D-Vd group and 35 (14%) in the Vd group were categorized as high risk.RESULTS: After a median follow-up of 40.0 months, D-Vd prolonged median PFS versus Vd in patients with standard (16.6 vs 6.6 months; HR, 0.26; 95% CI, 0.19-0.37; P < 0.0001) and high (12.6 vs 6.2 months; HR, 0.41; 95% CI, 0.21-0.83; P = 0.0106) cytogenetic risk. D-Vd achieved deep responses, including higher rates of MRD negativity and sustained MRD negativity versus Vd, regardless of cytogenetic risk. The safety profile was consistent with the overall population of CASTOR.CONCLUSION: These updated data reinforce the effectiveness and tolerability of daratumumab-based regimens for RRMM, regardless of cytogenetic risk status.TRIAL REGISTRATION: ClinicalTrials.gov, NCT02136134 . Registered 12 May 2014.

U2 - 10.1186/s13045-020-00948-5

DO - 10.1186/s13045-020-00948-5

M3 - SCORING: Journal article

C2 - 32819447

VL - 13

SP - 115

JO - J HEMATOL ONCOL

JF - J HEMATOL ONCOL

SN - 1756-8722

IS - 1

ER -